Published in Hepatitis Weekly, September 23rd, 2002
Loss from continuing operations for the 3 months ended June 30, 2002 declined to $(293,893), or $(0.04) per diluted share, compared with a loss from continuing operations of $(886,866), or $(0.14) per diluted share, for the 3 months ended March 31, 2002.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.